Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03504852 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
A Phase 3 study of Moderate to Severe Chronic Plaque-Type Psoriasis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 331
- Enrollment target
- 20
- Study locations
NCT03504852 is a Phase 3 study of Moderate to Severe Chronic Plaque-Type Psoriasis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 331 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT03504852, a Phase 3 study of Moderate to Severe Chronic Plaque-Type Psoriasis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 331 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
Conditions Studied
Interventions
- DRUG secukinumab 150 mg
Study Locations (20)
California
- Novartis Investigative Site - Irvine
- Novartis Investigative Site - Sacramento
- Novartis Investigative Site - Sacramento
- Novartis Investigative Site - San Diego
- Novartis Investigative Site - Santa Monica
Florida
- Novartis Investigative Site - Tampa
- Novartis Investigative Site - West Palm Beach
Georgia
- Novartis Investigative Site - Alpharetta
- Novartis Investigative Site - Snellville
Indiana
- Novartis Investigative Site - Indianapolis
- Novartis Investigative Site - New Albany
Kentucky
- Novartis Investigative Site - Louisville
- Novartis Investigative Site - Owensboro
Alabama
- Novartis Investigative Site - Birmingham
Arizona
- Novartis Investigative Site - Phoenix
Arkansas
- Novartis Investigative Site - Rogers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 331 participants |
| Start Date | 2018-06-25 |
| Est. Completion | 2020-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03504852
The ClinicalTrials.gov registry entry for NCT03504852 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 331 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate to Severe Chronic Plaque-Type Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which secukinumab 150 mg is the first listed.
NCT03504852 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT03504852 about?
NCT03504852 is a clinical study titled "Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis". The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
What is the current status of trial NCT03504852?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 331 participants. The study started on 2018-06-25. Estimated completion is 2020-07-15.
What conditions does trial NCT03504852 study?
This clinical trial studies the following conditions: Moderate to Severe Chronic Plaque-Type Psoriasis.
What interventions are being tested in trial NCT03504852?
The interventions under investigation include: secukinumab 150 mg (DRUG).
Who is sponsoring clinical trial NCT03504852?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03504852 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate to Severe Chronic Plaque-Type Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.